Jazz Pharmaceuticals plc (JAZZ) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and thank you for standing by. Welcome to Jazz Pharmaceuticals' second quarter 2026 earnings conference call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. Please note that today's conference is being recorded. I will now hand the conference over to your first speaker today, John Bluth, VP and Head of Investor Relations. Please go ahead. Thank you and good afternoon everyone. Today, Jazz Pharmaceuticals reported its second quarter 2026 financial results. The slide presentation accompanying this webcast is available on the investor section of our website along with the press release and quarterly report on form 10-Q for the second quarter ended June 30, 2026. On the call today are Renee Gala, President and Chief Executive Officer, Sam Pearce, Chief Commercial Officer, Robbie Iannone, Global Head of R&D and Chief Medical Officer, and Phil Johnson, Chief Financial Officer. On slide two, I'd like to remind you that today's webcast includes forward-looking statements such as those related to our future financial and operating results, growth potential and anticipated development, regulatory and commercial milestones, which involve risks and uncertainties that could cause actual events, performance, and results to differ materially from those contained in these forward-looking statements. We encourage you to review these risks and uncertainties described in today's press release and under the caption risk factors in our annual report on Form 10-K for the fiscal year ended December 31st, 2025. We undertake no duty or obl...